Company Profile For OSI Pharmaceuticals, Inc.

OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. Roche Holding Ltd. and OSI announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy. In December 2008, the Company acquired from 7TM Pharma A/S, a number of early stage research assets and a G-Protein coupled receptor (GPCR), technology platform.

BRIEF: For the nine months ended 30 September 2009, OSI Pharmaceuticals, Inc.'s revenues increased 8% to $304.2M. Net income from continuing operations decreased 46% to $50.5M.Revenues reflect increased income from royalties on product licenses. Net income was offset by an increase in research & development expenses, higher selling, general & administrative expenses and presence of research & devolopment & restruturing costs.